drugset / Trial / NCT04629443
Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety, tolerability and clinical activity of the combination S64315 with azacitidine in patients with acute myeloid leukaemia.
Timeline
- Start
- 2021-02-17
- Primary completion
- 2023-08-25
- Completion
- 2023-08-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MIK665 | Unknown | 50 mg | Intravenous |
| Subject | MIK665 | Unknown | 250 mg | Intravenous |
| Background | Azacitidine | Other / unclassified | 75 mg/m2 | Subcutaneous |